503-69-5

Upstream product

• 156-62-7 calcium cyanamide 
• 22113-86-6 ethylammonium nitrate 
• 674-81-7 nitrosoguanidine 
• 75-04-7 ethylamine 
• 2986-30-3 S-(3-hydroxy-propyl)-isothiourea 
• 14527-26-5 2-methylisothiourea sulphate 
• 53114-57-1 S-methylisothiourea hydrochloride 
• 127099-85-8 N-Cyanoguanidine 
• 867-44-7 S-Methylisothiourea sulfate 
• 7732-18-5 water 
• 44595-80-4 N-ethyl-S-methyl-isothiourea 
• 147895-43-0 S-methylisothiourea hemisulphate 
• 420-04-2 CYANAMID 
• 3482-86-8 N-ethylguanidine hemisulfate 

Downstream Products

• 101087-42-7 ethylcarbamimidoyl-amidophosphoric acid diphenyl ester 
• 91457-53-3 N-[2-(2,6-Dichloro-phenyl)-acetyl]-N'-ethyl-guanidine 
• 85562-96-5 1-(2-methylphenyl)-3-ethylamidinourea 
• 65009-17-8 1-[1-Amino-1-ethylamino-meth-(Z)-ylidene]-3-(2,6-dimethyl-phenyl)-urea 
• 36946-02-8 2-Amino-5-butyl-3-ethyl-6-methyl-4-pyrimidinone 
• 23947-60-6 ethirimol 
• 137279-29-9 2-Ethylaminopyrimidine-5-carboxaldehyde 
• 338792-66-8 C₇H₈F₃N₃O 
• 1441961-34-7 2-(ethylamino)-4,6-diphenylpyrimidine-5-carbonitrile 
• 5734-69-0 2-ethylamino-4-hydroxy-6-methylpyrimidine 
• 79680-45-8 2-(Ethylamino)-5,6-dihydro-5,6-trans-diphenyl-4(1H)-pyrimidinon 

Relevant academic research and scientific papers

Continuous synthesis method of hydroxypyrimidine compound

The invention discloses a continuous synthesis method of a hydroxypyrimidine compound. The method comprises the steps: carrying out continuous reaction on organic amine and a 50% cyanamide aqueous solution in a micro-reactor, introducing the reaction solution into a liquid separator for continuous phase splitting, carrying out continuous ring closing on a guanidine solution and alpha-alkyl acetoacetate in a second micro-reactor, washing the reaction solution with water, and desolventizing to obtain a target product. The method is based on the concept of green chemistry, the comprehensive costof raw materials is far lower than that of traditional methods, no salt-containing wastewater is generated, and treatment is easy; traditional solid-liquid separation is avoided, automatic productionis facilitated, and the safety and environmental protection level of the device is improved; continuous synthesis is adopted, decomposition of an intermediate is avoided, the total yield is larger than 82%, and the product content reaches 98%.

Visible Light-Induced Aerobic Epoxidation of α,β-Unsaturated Ketones Mediated by Amidines

An aerobic photoepoxidation of α,β-unsaturated ketones driven by visible light in the presence of tetramethylguanidine (3b), tetraphenylporphine (H2TPP), and molecular oxygen under mild conditions was revealed. The corresponding α,β-epoxy ketones were obtained in yields of up to 94% in 96 h. The reaction time was shortened to 4.6 h by flow synthesis. The mechanism related to singlet oxygen was supported by experiments and density functional theory (DFT) calculations.

Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2

The discovery and optimization of a series of tetrahydropyridopyrimidine based extracellular signal-regulated kinase (Erks) inhibitors discovered via HTS and structure based drug design is reported. The compounds demonstrate potent and selective inhibition of Erk2 and knockdown of phospho-RSK levels in HepG2 cells and tumor xenografts.

Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2

The discovery and optimization of a series of tetrahydropyridopyrimidine based extracellular signal-regulated kinase (Erks) inhibitors discovered via HTS and structure based drug design is reported. The compounds demonstrate potent and selective inhibition of Erk2 and knockdown of phospho-RSK levels in HepG2 cells and tumor xenografts.

Synthesis of novel strobilurin-pyrimidine derivatives and their antiproliferative activity against human cancer cell lines

A series of new strobilurin-pyrimidine analogs were designed and synthesized based on the structures of our previously discovered antiproliferative compounds I and II. Biological evaluation with two human cancer cell lines (A549 and HL60) showed that most of these compounds possessed moderate to potent antiproliferative activity. Two potent candidates (8f, IC50 = 2.2 nM and 11d, IC50 = 3.4 nM) were identified with nanomolar activity against leukemia cancer cell line HL60 for further development. This activity represents a 1000- to 2500-fold improvement compared to the parent compounds I and II and is 20- to 30-fold better than the chemotherapy drug, doxorubicin. The present work provides strong incentive for further development of these strobilurin-pyrimidine analogs as potential antitumor agents for the treatment of leukemia.

A novel, broad-spectrum anticancer compound containing the imidazo[4,5-e][1,3]diazepine ring system

Synthesis and broad-spectrum anticancer activity of a novel heterocyclic compound 1 containing the title imidazo[4,5-e][1,3]diazepine ring system have been reported. The compound shows potent in vitro antitumor activity with low micromolar IC50's against prostate, lung, breast, and ovarian cancer cell lines tested. The long alkyl chain attached to the six-position of the heterocyclic ring of 1 appears to be necessary for the observed biological activity.

Novel compounds and methods for synthesis and therapy

Novel compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.

Compounds and methods for synthesis and therapy

Novel compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.

POLYHYDROXY BENZOIC ACID DERIVATIVES AND THEIR USE AS NEURAMINIDASE INHIBITORS

The present invention is directed to compositions of the formula: wherein: R2 is H, or an alkyl group having 1 to 3 carbon atoms and 0 to 2 hydroxyls; R3 is H, or hydroxyl; R4 is H, or forms a hydrolyzable ester or amide with -C02-; R5 are H, or are taken together to form =NH; and R6 comprises an amine, or a group having 1 to 12 carbon atoms and 1 to 3 amine groups. The invention is also directed to methods of inhibiting the activity of neuraminidase using the compounds of the invention

CARBOCYCLIC COMPOUNDS

Novel carbocyclic compounds are described. The compounds generally comprise an acidic group, a basic group, a substituted amino or N-acyl and a group having an optionally hydroxylated alkane moiety. Pharmaceutical compositions comprising the inhibitors of the invention are also described. Methods of inhibiting neuraminidase in samples suspected of containing neuraminidase are also described. Antigenic materials, polymers, antibodies, conjugates of the compounds of the invention with labels, and assay methods for detecting neuraminidase activity are also described.